- Home
- MCW vs TRVI Comparison
MCW vs TRVI Comparison
Compare MCW & TRVI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | MCW | TRVI |
|---|---|---|
| Founded | 1996 | 2011 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | | Biotechnology: Pharmaceutical Preparations |
| Sector | | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.5B | 1.4B |
| IPO Year | 2021 | 2019 |
Fundamental Metrics
Financial Performance| Metric | MCW | TRVI |
|---|---|---|
| Price | $5.24 | $13.44 |
| Analyst Decision | Buy | Strong Buy |
| Analyst Count | 11 | 11 |
| Target Price | $7.68 | ★ $20.59 |
| AVG Volume (30 Days) | 1.3M | ★ 2.1M |
| Earning Date | 10-29-2025 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 22.84 | N/A |
| EPS | ★ 0.27 | N/A |
| Revenue | ★ $1,041,660,000.00 | N/A |
| Revenue This Year | $6.86 | N/A |
| Revenue Next Year | $6.87 | N/A |
| P/E Ratio | $19.42 | ★ N/A |
| Revenue Growth | ★ 6.98 | N/A |
| 52 Week Low | $4.61 | $2.36 |
| 52 Week High | $8.60 | $14.00 |
Technical Indicators
Market Signals| Indicator | MCW | TRVI |
|---|---|---|
| Relative Strength Index (RSI) | 51.68 | 69.05 |
| Support Level | $5.19 | $12.75 |
| Resistance Level | $5.35 | $14.00 |
| Average True Range (ATR) | 0.17 | 0.78 |
| MACD | 0.02 | 0.15 |
| Stochastic Oscillator | 68.22 | 84.04 |
Price Performance
Historical ComparisonAbout MCW Mister Car Wash Inc.
Mister Car Wash Inc is a car wash brand offering express exterior and interior cleaning services. Express Exterior Locations offers express exterior cleaning services and Interior Cleaning Locations offers both express exterior and interior cleaning services. The company recognizes revenue from activities related to providing car wash services at its car wash locations that are geographically diversified throughout the United States and have similar economic characteristics and nature of services.
About TRVI Trevi Therapeutics Inc.
Trevi Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the development and commercialization of the investigational therapy Haduvio (oral nalbuphine ER) for the treatment of chronic cough in adults with idiopathic pulmonary fibrosis, or IPF, and other chronic cough indications, and for the treatment of prurigo nodularis. Haduvio is an oral extended-release formulation of nalbuphine.